title: Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var. canis infestation in dogs.
abstract: The efficacy of fluralaner, formulated as a chewable tablet (Bravecto™) or topical solution (Bravecto™ Spot-on Solution), was evaluated against naturally acquired Sarcoptes scabiei var. canis infestation in dogs.
  
  
  
  The study was performed in privately-owned dogs naturally infested with S. scabiei var. canis. All dogs living in the same household as the infested dog were enrolled into one of 3 groups (2 fluralaner treated and 1 negative control). All dogs within one household were administered the same treatment, with one dog per household included in further observations and assessments. In total, 29 dogs confirmed positive for sarcoptic mange were included. On Day 0, all dogs in group 1 (n = 9) were treated once orally with fluralaner at a minimum dose of 25 mg/kg body weight; all dogs in group 2 (n = 11) were treated once topically with fluralaner at a dose of 25 mg/kg body weight; and dogs in group 3 (n = 9) were treated once topically with saline solution. Sarcoptes scabiei var. canis mites on each dog were counted before treatment and at 4 weeks after treatment in deep skin scrapings (~4 cm(2)) from 5 different body areas. Clinical signs of infestation (i.e. erythematous papules; casts, scales and crusts; body areas with hair loss) and pruritus were recorded at the same time points.
  
  
  
  Single oral or topical treatment with fluralaner resulted in a 100 % reduction in mite counts post-treatment (group 1: P = 0.0009 and group 2: P = 0.0011). Resolution of clinical signs at four weeks post-treatment was variable, with improvement observed for erythematous papules, casts and crusts, and pruritus. All fluralaner treated dogs showed an improvement in overall hair re-growth compared with pre-treatment observations.
  
  
  
  Fluralaner administered either orally or topically to naturally infested dogs eliminates Sarcoptes scabiei var. canis mites and improves clinical signs over a 4-week observation period.
authors.affiliation: MSD Animal Health Innovation GmbH, Zur Propstei, Schwabenheim, 55270, Germany. janina.taenzler@msd.de.
authors.forename: Janina
authors.initials: J
authors.lastname: Taenzler
authors.affiliation: ClinVet International, Uitsigweg, Bainsvlei, Bloemfontein, 9338, Free State, South Africa.
authors.forename: Julian
authors.initials: J
authors.lastname: Liebenberg
authors.affiliation: MSD Animal Health Innovation GmbH, Zur Propstei, Schwabenheim, 55270, Germany.
authors.forename: Rainer K A
authors.initials: RK
authors.lastname: Roepke
authors.affiliation: MSD Animal Health Innovation SAS, Beaucouzé Cedex, 49071, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Frénais
authors.affiliation: MSD Animal Health Innovation GmbH, Zur Propstei, Schwabenheim, 55270, Germany.
authors.forename: Anja R
authors.initials: AR
authors.lastname: Heckeroth
mesh_terms: D056810:Acaricides / Q000008:administration & dosage*; D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology; D004285:Dogs; D005260:Female; D007555:Isoxazoles / Q000008:administration & dosage*; D008297:Male; D012520:Sarcoptes scabiei / Q000187:drug effects*; D012532:Scabies / Q000188:drug therapy / Q000662:veterinary*; D013607:Tablets
chemical_list: C000591860:A1443 compound; D056810:Acaricides; D007555:Isoxazoles; D013607:Tablets
keywords: Bravecto™; Bravecto™ Spot-on Solution; Chewable tablets; Dog; Efficacy; Fluralaner; Mange; Mites; Oral; Sarcoptes scabiei var. canis; Topical